OasisLMS

Conference Attendees:  Free access to conference materials.

Non-Attendees: Discounted access to conference materials.

The 2026 Latin America Conference on Lung Cancer (LALCA), held in conjunction with the International Thymic Malignancy Interest Group (ITMIG) Annual Meeting, was help on November 12–14, 2026, in São Paulo, Brazil. Under the theme “Connecting Latin America to the Forefront of Cancer Treatment,” this multidisciplinary conference brings together international experts to share the latest research, advances, and best practices in thoracic oncology.

The scientific program features educational sessions, oral abstract presentations, and poster discussions covering lung cancer screening, clinical trials, surgery, radiation oncology, targeted therapies, immunotherapy, biomarkers, and evolving treatment strategies. The meeting also emphasizes patient advocacy, multidisciplinary collaboration, and opportunities to advance thoracic cancer care across Latin America and beyond.

The IASLC Latin America Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician associates.

• Carlos Gil Ferreira, MD, PhD
• Lilian Faroni, MD, PhD
• Clarissa Mathias, MD, PhD
• Ricardo Terra, MD, PhD
• William Nassib William, MD

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

If you need assistance with this activity, please email: education@iaslc.org.